A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma

@article{Mahalingam2017API,
  title={A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma},
  author={D. Mahalingam and C. Fountzilas and J. Moseley and Nicole Noronha and Hue Tran and Romit Chakrabarty and G. Selvaggi and M. Coffey and Brad J. Thompson and J. Sarantopoulos},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2017},
  volume={79},
  pages={697-703}
}
  • D. Mahalingam, C. Fountzilas, +7 authors J. Sarantopoulos
  • Published 2017
  • Medicine
  • Cancer Chemotherapy and Pharmacology
  • REOLYSIN® (pelareorep) is an investigational new drug, consisting of a live, replication-competent, Reovirus Type 3 Dearing strain in a proprietary formulation. Several preclinical and clinical trials with REOLYSIN® on a wide range of cancer indications have demonstrated antineoplastic activity on cells with activated RAS-signaling pathway. Furthermore, long-term survival benefits were evident in post-treatment patients indicating a potential antitumor immune response triggered by REOLYSIN… CONTINUE READING
    31 Citations
    Oncolytic Viruses for the Treatment of Metastatic Melanoma
    • 4
    The Role of Oncolytic Viruses in the Treatment of Melanoma
    • 11
    Clinical Application of Oncolytic Viruses: A Systematic Review
    • 3
    • PDF

    References

    SHOWING 1-10 OF 33 REFERENCES
    Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.
    • 91
    Phase II Trial of Intravenous Administration of Reolysin® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma.
    • 24
    Phase II Study of Paclitaxel and Carboplatin for Malignant Melanoma
    • 77
    Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells
    • 90
    Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
    • 1,244
    • PDF